Therapeutic Actions of the Thiazolidinediones in Alzheimer's Disease

PPAR Research

Volumn 2015, Issue , 2015, Pages

  Pérez, María José ^a   Quintanilla, Rodrigo A ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^b UNIVERSIDAD CIENTÍFICA DEL SUR   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMYLOID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TAU PROTEIN;

ALZHEIMER DISEASE; CELL FUNCTION; CLINICAL TRIAL (TOPIC); HUMAN; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PROTEIN SECRETION; REVIEW;

EID: 84947243229     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2015/957248     Document Type: Review

References (58)

1. D. Hirtz, D. J.Thurman, K. Gwinn-Hardy, M. Mohamed, A. R. Chaudhuri, and R. Zalutsky, "How common are the 'common' neurologic disorders?" Neurology, vol. 68, no. 5, pp. 326-337, 2007.
2. H. W. Querfurth and F. M. LaFerla, "Alzheimer's disease," The New England Journal of Medicine, vol. 362, no. 4, pp. 329-344, 2010.
3. Y.Huang and L.Mucke, "Alzheimermechanisms and therapeutic strategies," Cell, vol. 148, no. 6, pp. 1204-1222, 2012.
4. L. Bertram, C. M. Lill, and R. E. Tanzi, "The genetics of Alzheimer disease: back to the future," Neuron, vol. 68, no. 2, pp. 270-281, 2010.
5. S. H. Barage andK.D. Sonawane, "Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer's disease," Neuropeptides, vol. 52, pp. 1-18, 2015.
6. G. Razay, A. Vreugdenhil, and G. Wilcock, "The metabolic syndrome and Alzheimer disease," Archives of Neurology, vol. 64, no. 1, pp. 93-96, 2007.
7. M. Vanhanen, K. Koivisto, L. Moilanen et al., "Association of metabolic syndrome with Alzheimer disease: a populationbased study," Neurology, vol. 67, no. 5, pp. 843-847, 2006.
8. F. G. De Felice and S. T. Ferreira, "Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease," Diabetes, vol. 63, no. 7, pp. 2262-2272, 2014.
9. G. Bedse, F. Di Domenico, G. Serviddio, and T. Cassano, "Aberrant insulin signaling in Alzheimer's disease: current knowledge," Frontiers in Neuroscience, vol. 9, article 204, 2015.
10. J. A. Ros, P. Cisternas, M. Arrese, S. Barja, and N. C. Inestrosa, "Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum," Progress in Neurobiology, vol. 121, pp. 125-146, 2014.
11. E. Ginter and V. Simko, "Type 2 diabetes mellitus, pandemic in 21st century," Advances in Experimental Medicine and Biology, vol. 771, pp. 42-50, 2012.
12. P. Imfeld, M. Bodmer, S. S. Jick, and C. R. Meier, "Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study," Journal of the American Geriatrics Society, vol. 60, no. 5, pp. 916-921, 2012.
13. M. T. Heneka, A. Fink, and G. Doblhammer, "Effect of pioglitazone medication on the incidence of dementia," Annals of Neurology, vol. 78, no. 2, pp. 284-294, 2015.
14. B. Desvergne, L. Michalik, and W. Wahli, "Transcriptional regulation of metabolism," Physiological Reviews, vol. 86, no. 2, pp. 465-514, 2006.
15. L. Gelman, J. N. Feige, and B. Desvergne, "Molecular basis of selective PPAR modulation for the treatment of Type 2 diabetes," Biochimica et Biophysica Acta-Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 1094-1107, 2007.
16. J. M. Zolezzi and N. C. Inestrosa, "Peroxisome proliferatoractivated receptors and alzheimer's disease: hitting the bloodbrain barrier," Molecular Neurobiology, vol. 48, no. 3, pp. 438-451, 2013.
17. H. Cheng, Y. Shang, L. Jiang et al., "The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis,"The International Journal of Neuroscience, 2015.
18. A. Burns, R. Jacoby, and R. Levy, "Psychiatric phenomena in Alzheimer's disease. I: disorders of thought content," The British Journal of Psychiatry, vol. 157, pp. 72-94, 1990.
19. Neha, R. K. Sodhi, A. S. Jaggi, and N. Singh, "Animal models of dementia and cognitive dysfunction," Life Sciences, vol. 109, no. 2, pp. 73-86, 2014.
20. L.Ma, Z. Shao, R.Wang et al., "Rosiglitazone improves learning and memory ability in rats with type 2 diabetes through the insulin signaling pathway," The American Journal of theMedical Sciences, vol. 350, no. 2, pp. 121-128, 2015.
21. S. Xu, Q. Guan, C. Wang et al., "Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses," Neuroscience Letters, vol. 578, pp. 7-11, 2014.
22. P. Papadopoulos, P. Rosa-Neto, J. Rochford, and E. Hamel, "Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in amouse model of Alzheimer's disease with combined amyloid-beta and cerebrovascular pathology," PLoS ONE, vol. 8, no. 7,Article ID e68612, 2013.
23. L. Escribano, A.-M. Simón, E. Gimeno et al., "Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology," Neuropsychopharmacology, vol. 35, no. 7, pp. 1593-1604, 2010.
24. J. L. Searcy, J. T. Phelps, T. Pancani et al., "Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of alzheimer's disease," Journal of Alzheimer's Disease, vol. 30, no. 4, pp. 943-961, 2012.
25. Y. Yu, X. Li, J. Blanchard et al., "Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice," Journal of Neural Transmission, vol. 122, no. 4, pp. 593-606, 2015.
26. S.Mandrekar-Colucci, J. C. Karlo, and G. E. Landreth, "Mechanisms underlying the rapid peroxisome proliferator-activated receptor-gamma-mediated amyloid clearance and reversal of cognitive deficits in amurinemodel of Alzheimer's disease,"The Journal of Neuroscience, vol. 32, no. 30, pp. 10117-10128, 2012.
27. J.-A. O'Reilly and M. Lynch, "Rosiglitazone improves spatial memory and decreases insoluble A1?42 in APP/PS1 mice," Journal of Neuroimmune Pharmacology, vol. 7, no. 1, pp. 140-144, 2012.
28. J. Chen, S. Li,W. Sun, J. Li, and J. Padmanabhan, "Anti-diabetes drug pioglitazone ameliorates synaptic defects inADtransgenic mice by inhibiting cyclin-dependent kinase5 activity," PLOS ONE, vol. 10, no. 4, Article IDe0123864, 2015.
29. E. M. Toledo and N. C. Inestrosa, "Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1?E9 mouse model of Alzheimer's disease," Molecular Psychiatry, vol. 15, no. 3, pp. 272-285, 2010.
30. J. B. Jahrling, C. M. Hernandez, L. Denner, and K. T. Dineley, "PPARgamma recruitment to active ERK during memory consolidation is required for Alzheimer's disease-related cognitive enhancement,"The Journal of Neuroscience, vol. 34, no. 11, pp. 4054-4063, 2014.
31. G. Q. Xiang, S. S. Tang, L. Y. Jiang et al., "PPAR agonist pioglitazone improves scopolamine-induced memory impairment in mice," The Journal of Pharmacy and Pharmacology, vol. 64, no. 4, pp. 589-596, 2012.
32. A. Prakash and A. Kumar, "Role of nuclear receptor on regulation of BDNF and neuroinflammation in hippocampus of -amyloid animal model of Alzheimer's disease," Neurotoxicity Research, vol. 25, no. 4, pp. 335-347, 2014.
33. A. Pisanu, D. Lecca, G. Mulas et al., "Dynamic changes in pro-and anti-inflammatory cytokines in microglia after PPAR-gamma agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease," Neurobiology of Disease, vol. 71, no. 1, pp. 280-291, 2014.
34. K. M. Lucin and T. Wyss-Coray, "Immune activation in brain aging and neurodegeneration: too much or too little?" Neuron, vol. 64, no. 1, pp. 110-122, 2009.
35. C. K. Combs, P. Bates, J. C. Karlo, and G. E. Landreth, "Regulation of -amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor ," Neurochemistry International, vol. 39, no. 5-6, pp. 449-457, 2001.
36. M. T. Heneka, G. E. Landreth, and M. Hüll, "Drug Insight: effects mediated by peroxisome proliferator-activated receptorgamma in CNS disorders," Nature Clinical Practice Neurology, vol. 3, no. 9, pp. 496-504, 2007.
37. E. Utreras, R. Hamada, M. Prochazkova et al., "Suppression of neuroinflammation in forebrain-specific Cdk5 conditional knockout mice by PPARgamma agonist improves neuronal loss and early lethality," Journal of Neuroinflammation, vol. 11, article 28, 2014.
38. R. A. Quintanilla, D. I. Orellana, C. Gonźalez-Billault, and R. B. Maccioni, "Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway," Experimental Cell Research, vol. 295, no. 1, pp. 245-257, 2004.
39. J. F.Castro-Alvarez, A. Uribe-Arias, D. Mejia-Raigosa, andG. P. Cardona-Gómez, "Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems biology approach," Frontiers in Aging Neuroscience, vol. 6, article 232, 2014.
40. M. M. Varnum and T. Ikezu, "The classification of microglial activation phenotypes on neurodegeneration and regeneration in alzheimer's disease brain," Archivum Immunologiae et Therapiae Experimentalis, vol. 60, no. 4, pp. 251-266, 2012.
41. M. T. Heneka, M. Sastre, L. Dumitrescu-Ozimek et al., "Acute treatment with the PPAR agonist pioglitazone and ibuprofen reduces glial inflammation and A1-42 levels in APPV717I transgenic mice," Brain, vol. 128, no. 6, pp. 1442-1453, 2005.
42. J. M. Castellano, J. Kim, F. R. Stewart et al., "Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance," Science TranslationalMedicine, vol. 3, no. 89, Article ID 89ra57, 2011.
43. K. G. Mawuenyega, W. Sigurdson, V. Ovod et al., "Decreased clearance of CNS -amyloid in Alzheimer's disease," Science, vol. 330, no. 6012, p. 1774, 2010.
44. M. Yamanaka, T. Ishikawa, A. Griep,D. Axt, M. P. Kummer, and M. T. Heneka, "PPARgamma/RXRalpha-induced and CD36-mediated microglial amyloid-beta phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice," The Journal of Neuroscience, vol. 32, no. 48, pp. 17321-17331, 2012.
45. J. C. Savage, T. Jay, E. Goduni et al., "Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease," The Journal of Neuroscience, vol. 35, no. 16, pp. 6532-6543, 2015.
46. M. E. Risner, A. M. Saunders, J. F. B. Altman et al., "Efficacy of rosiglitazone in a genetically defined population with mild-tomoderate Alzheimer's disease," Pharmacogenomics Journal, vol. 6, no. 4, pp. 246-254, 2006.
47. F. A. Cabezas-Opazo, K. Vergara-Pulgar, M. J. Perez, C. Jara, C. Osorio-Fuentealba, and R. A. Quintanilla, "Mitochondrial dysfunction contributes to the pathogenesis of Alzheimer's disease," Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 509654, 12 pages, 2015.
48. J. R. Colca,W. G.Mcdonald, and R. F. Kletzien, "Mitochondrial target of thiazolidinediones,"Diabetes, Obesity andMetabolism, vol. 16, no. 11, pp. 1048-1054, 2014.
49. D.-H. Cho, T. Nakamura, J. Fang et al., "S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury," Science, vol. 324, no. 5923, pp. 102-105, 2009.
50. M.-C. Chiang, Y.-C. Cheng, H.-M. Chen, Y.-J. Liang, and C.-H. Yen, "Rosiglitazone promotes neurite outgrowth and mitochondrial function inN2A cells via PPARgammapathway," Mitochondrion, vol. 14, no. 1, pp. 7-17, 2014.
51. X. Xu, Y. Lu, L. Chen, J. Chen, X. Luo, and X. Shen, "Identification of 15d-PGJ2 as an antagonist of farnesoid X receptor: molecular modeling with biological evaluation," Steroids, vol. 78, no. 9, pp. 813-822, 2013.
52. S. Roy, B. Zhang, V. M.-Y. Lee, and J. Q. Trojanowski, "Axonal transport defects: a common theme in neurodegenerative diseases," Acta Neuropathologica, vol. 109, no. 1, pp. 5-13, 2005.
53. C. D'Abramo, R. Ricciarelli, M. A. Pronzato, and P. Davies, "Troglitazone, a peroxisome proliferator-activated receptorgamma agonist, decreases tau phosphorylation in CHOtau4R cells," Journal of Neurochemistry, vol. 98, no. 4, pp. 1068-1077, 2006.
54. S.-Y. Yoon, J.-S. Park, J.-E. Choi et al., "Rosiglitazone reduces tau phosphorylation via JNK inhibition in the hippocampus of rats with type 2 diabetes and tau transfected SH-SY5Y cells," Neurobiology of Disease, vol. 40, no. 2, pp. 449-455, 2010.
55. A. W. M. To, E. M. Ribe, T. T. Chuang, J. E. Schroeder, and S. Lovestone, "The 3 and 4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice," PLoS ONE, vol. 6, no. 2, Article ID e16991, 2011.
56. D.-H. Cho, E. J. Lee, K. J. Kwon et al., "Troglitazone, a thiazolidinedione, decreases tau phosphorylation through the inhibition of cyclin-dependent kinase 5 activity in SH-SY5Y neuroblastoma cells and primary neurons," Journal of Neurochemistry, vol. 126, no. 5, pp. 685-695, 2013.
57. M. J. Ehret and K. W. Chamberlin, "Current practices in the treatment of alzheimer disease: where is the evidence after the phase iii trials?" Clinical Therapeutics, vol. 37, no. 8, pp. 1604-1616, 2015.
58. M. S. Rafii and P. S. Aisen, "Advances in Alzheimer's disease drug development," BMC Medicine, vol. 13, article 62, 2015.